A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Oct 2018
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms Discover 2
- Sponsors Janssen Research & Development
- 03 Oct 2018 Planned End Date changed from 18 Dec 2020 to 20 Oct 2021.
- 03 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2018 Planned End Date changed from 18 Jun 2021 to 18 Dec 2020.